rs140476054
Positions:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 1P and 5B. PP3BP6BS2
The NM_018100.4(EFHC1):c.731G>A(p.Arg244Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00015 in 1,613,180 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00012 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00015 ( 0 hom. )
Consequence
EFHC1
NM_018100.4 missense
NM_018100.4 missense
Scores
7
4
3
Clinical Significance
Conservation
PhyloP100: 6.04
Genes affected
EFHC1 (HGNC:16406): (EF-hand domain containing 1) This gene encodes an EF-hand-containing calcium binding protein. The encoded protein likely plays a role in calcium homeostasis. Mutations in this gene have been associated with susceptibility to juvenile myoclonic epilepsy and juvenile absence epilepsy. Alternatively spliced transcript variants have been described. [provided by RefSeq, Feb 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
PP3
?
MetaRNN computational evidence supports a deleterious effect, 0.771
BP6
?
Variant 6-52454102-G-A is Benign according to our data. Variant chr6-52454102-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 205388.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=2, Benign=1}.
BS2
?
High AC in GnomAd4 at 19 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
EFHC1 | NM_018100.4 | c.731G>A | p.Arg244Gln | missense_variant | 5/11 | ENST00000371068.11 | |
EFHC1 | NM_001172420.2 | c.674G>A | p.Arg225Gln | missense_variant | 6/12 | ||
EFHC1 | NR_033327.2 | n.2057G>A | non_coding_transcript_exon_variant | 4/10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
EFHC1 | ENST00000371068.11 | c.731G>A | p.Arg244Gln | missense_variant | 5/11 | 1 | NM_018100.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.000125 AC: 19AN: 152002Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
19
AN:
152002
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000955 AC: 24AN: 251272Hom.: 0 AF XY: 0.0000663 AC XY: 9AN XY: 135826
GnomAD3 exomes
AF:
AC:
24
AN:
251272
Hom.:
AF XY:
AC XY:
9
AN XY:
135826
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000153 AC: 223AN: 1461060Hom.: 0 Cov.: 34 AF XY: 0.000129 AC XY: 94AN XY: 726858
GnomAD4 exome
AF:
AC:
223
AN:
1461060
Hom.:
Cov.:
34
AF XY:
AC XY:
94
AN XY:
726858
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.000125 AC: 19AN: 152120Hom.: 0 Cov.: 32 AF XY: 0.000148 AC XY: 11AN XY: 74360
GnomAD4 genome
?
AF:
AC:
19
AN:
152120
Hom.:
Cov.:
32
AF XY:
AC XY:
11
AN XY:
74360
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
3
ExAC
?
AF:
AC:
8
Asia WGS
AF:
AC:
1
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Absence seizure;C1850778:Myoclonic epilepsy, juvenile, susceptibility to, 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Invitae | Aug 17, 2023 | This variant has not been reported in the literature in individuals affected with EFHC1-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt EFHC1 protein function. ClinVar contains an entry for this variant (Variation ID: 205388). This variant is present in population databases (rs140476054, gnomAD 0.02%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 244 of the EFHC1 protein (p.Arg244Gln). - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 22, 2015 | p.Arg244Gln (CGA>CAA): c.731 G>A in exon 5 of the EFHC1 gene (NM_018100.3). The Arg244Gln missense substitution has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The amino acid substitution is non-conservative, as a positively charged Arginine residue is replaced by an uncharged Glutamine residue. Arg244Gln alters a position that is highly conserved across species and in related proteins. This variant lies within the second DM10 domain of the protein, and missense mutations altering nearby codons in this domain have been reported in association with epilepsy (Suzuki et al., 2004; Bai et al., 2009). Multiple in silico models predict Arg244Gln may be damaging to protein structure/function. Based on the available information, Arg244Gln is a candidate for a disease-causing mutation, but the possibility that it is a rare benign variant cannot be excluded. The variant is found in EPILEPSY panel(s). - |
Epilepsy, idiopathic generalized, susceptibility to, 7 Benign:1
Benign, criteria provided, single submitter | research | Experimental Epileptology, AG Lerche, Hertie Institute for Clinical Brain Research | Jan 02, 2022 | ACMG/AMP criteria: PP3, BS1, BS4 - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Benign
T;.;.;D;T;T;T;T;T;.;T;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;.;D;D;D;D;D;D;D;D;.;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationTaster
Benign
D;D;D
PrimateAI
Uncertain
T
Polyphen
1.0
.;.;.;D;.;.;.;.;.;.;.;.;.
Vest4
0.92, 0.94
MVP
0.97
MPC
0.50
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at